Diabetes area patent participation analysis – part II: years 2011-2016

References

• Kasuga M. Insulin resistance and pancreatic β cell failure. J Clin Invest. 2006;116(7):1756–1760.
   PubMed Web of Science ®Google Scholar
• Seshasai SRK, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841.
   PubMed Web of Science ®Google Scholar
• Anonymous National Diabetes Statistics Report. 2017. Estimates of Diabetes and Its Burden in the United States. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
   Google Scholar
• Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff. 2010;29(2):297–303.
   PubMed Web of Science ®Google Scholar
• Anonymous. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl1):S64–S74.
   PubMedGoogle Scholar
• Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obes Metab. 2016;18(4):333–347.
   PubMed Web of Science ®Google Scholar
• Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20(4):573–591.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Polidori D, Zambrowicz B, et al. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport. Diabetes Care. 2015;38(12):2344–2353.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Invest Drugs. 2012;21(1):45–57.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38(2):89–101.
   PubMed Web of Science ®Google Scholar
• Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):27S–34S.
   PubMed Web of Science ®Google Scholar
• Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf. 2012;11(4):597–614.
   PubMed Web of Science ®Google Scholar
• Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383(9933):2008–2017.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Carpino PA, Goodwin B. Diabetes area participation analysis: a review of companies and targets described in the 2008-2010 patent literature. Expert Opin Ther Pat. 2010;20(12):1627–1651.
   PubMed Web of Science ®Google Scholar
• Denison H, Nilsson C, Loefgren L, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes, Obes Metab. 2014;16(4):334–343.
   PubMed Web of Science ®Google Scholar
• Ritter K, Buning C, Halland N, et al. G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J Med Chem. 2016;59(8):3579–3592.
   PubMed Web of Science ®Google Scholar
• Anderson A, Walker BR. 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs. 2013;73(13):1385–1393.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Dales NA, Winther MD. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease. J Med Chem. 2014;57(12):5039–5056.
   PubMed Web of Science ®Google Scholar
• Oballa RM, Belair L, Black WC, et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011;54(14):5082–5096.
   PubMed Web of Science ®Google Scholar
• Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(12):2560–2566.
   PubMed Web of Science ®Google Scholar
• Agius L. Lessons from glucokinase activators: the problem of declining efficacy. Expert Opin Ther Pat. 2014;24(11):1155–1159.
   PubMed Web of Science ®Google Scholar
• Wu M-F, Chang K-W, Zhou W, et al. Patent deployment strategies and patent value in LED industry. PLoS One. 2015;10(6):e0129911/1-e11/10.
   Web of Science ®Google Scholar
• Mohler ML, He Y, Wu Z, et al. Recent and emerging anti-diabetes targets. Med Res Rev. 2009;29(1):125–195.
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706–1713.
   PubMed Web of Science ®Google Scholar
• Gluchowski NL, Chitraju C, Picoraro JA, et al. Identification and characterization of a novel DGAT1 missense mutation associated with congenital diarrhea. J Lipid Res. 2017;58(6):1230–1237.
   PubMed Web of Science ®Google Scholar
• Bagley SW, Griffith DA, Kung DW-S N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors. US20110111046A1. 2011.
   Google Scholar
• Goff D, Payan D, Singh R, et al. Preparation of AMPK-activating N-containing heterocyclic compounds and use in treating metabolic-related disorders and other diseases. WO2012016217A1. 2012.
   Google Scholar
• Arroyo I, Krueger D, Chen P, et al. Preparation of novel crystalline forms of the dipeptidyl peptidase IV inhibitor (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine for the treatment of diabetes. WO2013003249A1. 2013.
   Google Scholar
• Qin D, Cheung M, Joshi H, et al. Preparation of aminooxotetrahdryooxepinopyrimidine derivatives for use as diacylglycerol acyltransferase inhibitors. WO2012162129A1. 2012.
   Google Scholar
• Eckhardt M, Frattini S, Hamprecht D, et al. Preparation of indanyloxydihydrobenzofuranylacetic acids as GPR40 receptor modulators for treating metabolic diseases. US20130252937A1. 2013.
   Google Scholar
• Berthel SJ, Kester RF, Orzechowski L Preparation of isoindolinone derivatives as glucokinase activators for treating metabolic diseases. WO2012150202A1. 2012.
   Google Scholar
• Bissantz C, Dehmlow H, Erickson SD, et al. Preparation of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide compounds. US20110178089A1. 2011.
   Google Scholar
• Kinzel O, Steeneck C, Kremoser C. Novel FXR (NR1H4) binding and activity modulating compounds. WO2013007387A1. 2013.
   Google Scholar
• Bebernitz GR, Bock MG, Reddy DS, et al. Preparation of glycoside derivatives as antidiabetic agents. WO2011048112A1. 2011.
   Google Scholar
• Mahajan A, Go MJ, Zhang W, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46(3):234–244.
   PubMed Web of Science ®Google Scholar